Circa’s biobased levoglucosenone derivative used in new manufacturing method

In Norway, Circa Group AS announced that its levoglucosenone derivative, made from waste, non-food biomass, has been used as an intermediate in an award-winning manufacture process for an investigational drug for leukaemia.

The 2022 Peter J. Dunn Award for Green Chemistry and Engineering Impact in the Pharmaceutical Industry recognised MSD for their work in developing green manufacturing technologies to enable the production of investigational leukaemia drug candidate from a biorenewable commodity material.

“This work demonstrates the potential of our bio-based platform molecule levoglucosenone (LGO) as a scaffold for the development of pharmaceuticals. I am delighted to see our products being used by a leading biopharmaceutical corporation, and in a way that delivers compelling environmental and efficiency improvements.” said Dr Jason Camp, CTO Circa Group.